Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13261664 | 0.74 | ALDH1A1 (0.43) | CYP2A6ALDH1A1CYP1A2TSHRHSD17B10 | |
| SCHEMBL8404419 | 0.73 | CYP1A2 (0.55) | CYP2A6ALDH1A1CYP1A2TSHRHSD17B10 | |
| SCHEMBL13261701 | 0.73 | CYP2A6 (0.38) | CYP2A6ALDH1A1CYP1A2TSHRHSD17B10 | |
| SCHEMBL2008188 | 0.72 | CYP2A6 (0.41) | CYP2A6ALDH1A1CYP1A2TSHRHSD17B10 | |
| SCHEMBL1097973 | 0.72 | CYP2A6 (0.41) | CYP2A6ALDH1A1CYP1A2TSHRHSD17B10 | |
| SCHEMBL15780702 | 0.71 | CCR4 (0.40) | CYP2A6ALDH1A1CYP1A2TSHRHSD17B10 | |
| SCHEMBL8404418 | 0.71 | CYP1A2 (0.48) | CYP2A6ALDH1A1CYP1A2HSD17B10TDP1 | |
| SCHEMBL8404417 | 0.71 | CYP1A2 (0.48) | CYP2A6ALDH1A1CYP1A2HSD17B10TDP1 | |
| SCHEMBL23029706 | 0.70 | SREBF2 (0.42) | CYP2A6ALDH1A1CYP1A2HSD17B10TDP1 | |
| SCHEMBL6313115 | 0.70 | CYP2A6 (0.48) | CYP2A6ALDH1A1CYP1A2TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3101017-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | claimed |
| EP-3101017-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2016-12-07 | — | — | EP | claimed |
| EP-2142534-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2016-08-10 | — | — | EP | claimed |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-01-28 | — | — | US | claimed |
| WO-2014111493-A1 | SUBSTITUTED BENZIMIDAZOLYL PHOSPHINE COMPOUNDS AND A METHOD FOR DECARBOXYLATING CARBON-CARBON LINKING | SALTIGO GMBH (DE) | 2014-07-24 | — | — | WO | claimed |
| US-8153659-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2012-04-10 | — | — | US | claimed |
| EP-2142534-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION | 2009-01-01 | — | — | US | claimed |
| WO-2008115516-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-09-25 | — | — | WO | claimed |
| EP-1089963-B1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2004-06-16 | — | — | EP | claimed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | claimed |
| US-6235753-B1 | TUMOR NECROSIS FACTOR; AUTOIMMUNE DISEASES; ANTIALLERGENS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | claimed |
| US-6218397-B1 | FOR THERAPY OF STRESS-RELATED ILLNESSES, SUCH AS STRESS-INDUCED DEPRESSION, ANXIETY, AND HEADACHE; ABDOMINAL BOWEL SYNDROME; INFLAMMATORY DISEASES; IMMUNE SUPPRESSION; ALZHEIMER'S DISEASE; GASTRONINTESTINAL DISEASES | PFIZER INC | 2001-04-17 | — | — | US | claimed |
| EP-0674642-B1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 2000-08-23 | — | — | EP | claimed |
| US-6051578-A | Pyrazolopyrimidines for treatment of CNS disorders | PFIZER INC. (US) | 2000-04-18 | — | — | US | claimed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | claimed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | claimed |
| EP-0729758-A2 | Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders | PFIZER INC. (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0674642-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994013677-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | CYP2A6 26/4885ALDH1A1 1376/4885CYP1A2 19/4885 |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | CYP2A6 26/4885ALDH1A1 1376/4885CYP1A2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.